Humana (NYSE:HUM) Given New $290.00 Price Target at Truist Financial

Humana (NYSE:HUM) had its target price boosted by Truist Financial from $260.00 to $290.00 in a research report released on Monday,Benzinga reports. They currently have a hold rating on the insurance provider’s stock.

HUM has been the topic of a number of other research reports. Leerink Partnrs downgraded Humana from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Cantor Fitzgerald restated a “neutral” rating and set a $395.00 target price on shares of Humana in a report on Tuesday, October 1st. Deutsche Bank Aktiengesellschaft decreased their target price on Humana from $349.00 to $250.00 and set a “hold” rating for the company in a research report on Thursday, October 3rd. Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and increased their price target for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th. Finally, Leerink Partners downgraded shares of Humana from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $400.00 to $250.00 in a research note on Wednesday, October 2nd. Twenty research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, Humana presently has a consensus rating of “Hold” and a consensus price target of $302.00.

Humana Stock Up 0.4 %

Shares of HUM opened at $263.54 on Monday. The firm has a market capitalization of $31.73 billion, a price-to-earnings ratio of 23.34, a PEG ratio of 2.12 and a beta of 0.55. Humana has a 52 week low of $213.31 and a 52 week high of $464.38. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The business’s fifty day moving average price is $272.64 and its two-hundred day moving average price is $312.79.

Humana (NYSE:HUM) last released its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. The company had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. On average, analysts predict that Humana will post 16.14 earnings per share for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 dividend on an annualized basis and a yield of 1.34%. Humana’s payout ratio is 31.36%.

Insiders Place Their Bets

In related news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.32% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in HUM. State Street Corp increased its position in Humana by 1.0% during the 3rd quarter. State Street Corp now owns 5,357,420 shares of the insurance provider’s stock worth $1,701,582,000 after purchasing an additional 53,272 shares in the last quarter. FMR LLC raised its position in Humana by 23.4% during the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after purchasing an additional 643,291 shares during the last quarter. Pzena Investment Management LLC grew its position in shares of Humana by 8.1% in the 3rd quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock valued at $793,830,000 after buying an additional 187,903 shares during the last quarter. Davis Selected Advisers increased its stake in shares of Humana by 16.1% in the second quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider’s stock valued at $863,640,000 after buying an additional 321,233 shares during the period. Finally, Marshall Wace LLP raised its position in shares of Humana by 118.9% during the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock worth $532,564,000 after acquiring an additional 774,085 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.